Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single arm open labeled multicentre phase 1b dose escalation study of carfilzomib taken in combination with thalidomide and dexamethasone in relapsed AL amyloidosis (CATALYST Trial)

Next Previous
Search
Trial Profile

A single arm open labeled multicentre phase 1b dose escalation study of carfilzomib taken in combination with thalidomide and dexamethasone in relapsed AL amyloidosis (CATALYST Trial)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Acronyms CATALYST
  • Sponsors Amgen

    • Most Recent Events

    • 10 Dec 2019 Results (Data cut of June 2019; n=10) assessing safety,tolerability and dose escalation of Carfilzomib-Thalidomide-Dexamethasone presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 02 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 11 Aug 2016 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top